NASDAQ:KRRO Korro Bio (KRRO) Stock Price, News & Analysis $13.38 +0.10 (+0.72%) As of 09:34 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Korro Bio Stock (NASDAQ:KRRO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Korro Bio alerts:Sign Up Key Stats Today's Range$13.10▼$13.1050-Day Range$10.07▼$14.7252-Week Range$5.20▼$55.89Volume235 shsAverage Volume198,653 shsMarket Capitalization$197.01 millionP/E RatioN/ADividend YieldN/APrice Target$16.71Consensus RatingModerate Buy Company Overview Korro Bio, Inc. is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases. The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics. Lead candidate KB103 is an investigational enzyme replacement therapy designed to address congenital hyperbilirubinemia by restoring deficient UGT1A1 activity. In parallel, Korro Bio is advancing a portfolio of live microbial drug candidates aimed at modulating the human microbiome to treat unmet medical needs in gastroenterology and oncology. These programs reflect the company’s dual focus on systemic enzyme therapies and targeted microbial approaches. Founded in 2019 and headquartered in Boston, Massachusetts, Korro Bio completed its initial public offering on the Nasdaq under the ticker KRRO in late 2021. The company collaborates with leading academic and industry partners to expand its enzyme discovery platform and accelerate translational research. Led by an experienced management team with backgrounds in biotherapeutics, protein science and drug development, Korro Bio serves a global pharmaceutical customer base and is committed to advancing innovative treatments from bench to bedside.AI Generated. May Contain Errors. Read More Korro Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreKRRO MarketRank™: Korro Bio scored higher than 66% of companies evaluated by MarketBeat, and ranked 248th out of 915 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingKorro Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 3 strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialKorro Bio has a consensus price target of $16.71, representing about 25.9% upside from its current price of $13.28.Amount of Analyst CoverageKorro Bio has only been the subject of 3 research reports in the past 90 days.Read more about Korro Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Korro Bio are expected to grow in the coming year, from ($4.97) to ($4.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Korro Bio is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Korro Bio is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKorro Bio has a P/B Ratio of 2.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.26% of the float of Korro Bio has been sold short.Short Interest Ratio / Days to CoverKorro Bio has a short interest ratio ("days to cover") of 9.16.Change versus previous monthShort interest in Korro Bio has recently decreased by 1.42%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKorro Bio does not currently pay a dividend.Dividend GrowthKorro Bio does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.06 News SentimentKorro Bio has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Korro Bio this week, compared to 3 articles on an average week. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Korro Bio insiders have sold 5,406.00% more of their company's stock than they have bought. Specifically, they have bought $78,815.00 in company stock and sold $4,339,553.00 in company stock.Percentage Held by Insiders4.80% of the stock of Korro Bio is held by insiders.Percentage Held by Institutions13.18% of the stock of Korro Bio is held by institutions.Read more about Korro Bio's insider trading history. Receive KRRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Korro Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KRRO Stock News HeadlinesKorro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 14 at 4:05 PM | globenewswire.comKorro Bio (NASDAQ:KRRO) Major Shareholder Acquires $19,283.78 in StockAugust 14 at 7:51 AM | insidertrades.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.August 17 at 1:00 AM | Reagan Gold Group (Ad)What is HC Wainwright's Forecast for Korro Bio Q3 Earnings?August 13, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Halozyme (HALO) and Resmed (RMD)August 12, 2026 | theglobeandmail.comWall Street Zen Upgrades Korro Bio (NASDAQ:KRRO) to SellAugust 8, 2026 | americanbankingnews.comKorro Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 6, 2026 | globenewswire.comKorro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 10, 2026 | globenewswire.comSee More Headlines KRRO Stock Analysis - Frequently Asked Questions How have KRRO shares performed this year? Korro Bio's stock was trading at $8.01 at the beginning of the year. Since then, KRRO stock has increased by 65.8% and is now trading at $13.28. How were Korro Bio's earnings last quarter? Korro Bio, Inc. (NASDAQ:KRRO) issued its earnings results on Thursday, August, 6th. The company reported ($1.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.34) by $0.27. The company earned $1.50 million during the quarter, compared to analyst estimates of $0.21 million. Korro Bio had a negative net margin of 1,834.48% and a negative trailing twelve-month return on equity of 114.26%. When did Korro Bio IPO? Korro Bio (KRRO) raised $90 million in an initial public offering on Thursday, October 3rd 2019. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. Who are Korro Bio's major shareholders? Top institutional investors of Korro Bio include BlackRock Inc. (5.67%), ADAR1 Capital Management LLC (3.67%), Walleye Capital LLC (0.38%) and Bank of America Corp DE (0.35%). Insiders that own company stock include Lynx1 Capital Management Lp, Paul Edward Walker, Mohamad Makhzoumi, Enterprise Associates 17 New, Anthony A Jr Florence, Rick Yang, Venture Opportunity Fund Atlas, Jean Francois Formela, Ram Aiyar, David L Lucchino, Loic A Vincent, Todd Chappell and Vineet Agarwal. View institutional ownership trends. How do I buy shares of Korro Bio? Shares of KRRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Korro Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Korro Bio investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings8/06/2026Today8/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 KRRO's financial health is in the Green zone, according to TradeSmith. KRRO has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KRRO Previous SymbolNASDAQ:KRRO CIK1703647 Webwww.frequencytx.com Phone781-315-4600FaxN/AEmployees70Year Founded2018Price Target and Rating Average Price Target for Korro Bio$16.71 High Price Target$23.00 Low Price Target$10.00 Potential Upside/Downside+25.9%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($10.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$117.26 million Net Margins-1,834.48% Pretax Margin-4,441.85% Return on Equity-114.26% Return on Assets-68.57% Debt Debt-to-Equity RatioN/A Current Ratio9.55 Quick Ratio9.55 Sales & Book Value Annual Sales$6.39 million Price / Sales30.61 Cash FlowN/A Price / Cash FlowN/A Book Value$5.46 per share Price / Book2.43Miscellaneous Outstanding Shares14,730,000Free Float14,019,000Market Cap$195.61 million OptionableNo Data Beta3.04 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:KRRO) was last updated on 8/17/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Korro Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Korro Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
